Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

NCT07407465 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Colorectal Adenocarcinoma
Rectal Adenocarcinoma
Rectal Cancer, Adenocarcinoma
Rectal Cancer, Metastatic
Colon Cancer Metastatic
Colon Cancer Adenocarcinoma

Interventions

DRUG: Trastuzumab-Deruxtecan (T-DXd)
DRUG: Capecitabine
DRUG: Bevacizumab

Sponsor

Gruppo Oncologico del Nord-Ovest

Collaborators

[object Object]